|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
DxS Ltd Appoints Patrik Dahlen as Non-Executive Director
9/10/2009 1:41:41 PM
Manchester, 9 September 2009. DxS Ltd, a personalised medicine company and leader in the provision of companion diagnostics, has today announced the appointment of Dr. Patrik Dahlen as non-executive director. As the former CEO of global cancer diagnostics company Dako, Dr. Dahlen will bring invaluable industry insight and a fresh persepective to DxS during the company’s continued period of expansion.
Dr. Dahlen has occupied high level positions within the diagnostics and life sciences sector for over 15 years. Prior to his four year tenure at Dako from 2005 to January 2009 Dr. Dahlen was CEO of the Danish biotech company Biolmage and previous to that president of lifesciences and senior vice president at PerkinElmer. Dr. Dahlen currently holds other board positions which include Proxeon and Olink and has been a board member for DakoCytomation and Cantion.
Commenting on his appointment, Dr. Dahlen said: “I am delighted to be joining DxS as a non-executive director. DxS is an exciting company in a very strong growth phase, and I believe that my experience in cancer diagnostics and companion diagnostics will further benefit the company."
Dr. Stephen Little, CEO of DxS said: “Patrik is a well respected figure in the sphere of cancer diagnostics with a great knowledge of the industry. His extensive expertise will be invaluable as DxS continues to expand and evolve.”
Dr. Dahlen’s appointment is part of DxS’ continuing plan for growth, which has seen the company more than double in size within the last twelve months with new manufacturing space taken on their Manchester site. In 2008 DxS signed a global distribution agreement with Roche Molecular Diagnostics for their TheraScreen® brand of diagnostics kits, and a deal which seen Amgen and Merck Serono/Bristol Myers Squibb use DxS’ TheraScreen: K-RAS Mutation Kit as a companion diagnostic for the colorectal cancer treatment Vectibix® and Eribitx®. In May DxS announced a deal with Boehringer Ingleheim to provide a companion diagnostic test kit for BIBW 2992 (Tovok™), and in July a deal with AstraZeneca to develop a companion diagnostic for use with IRESSA™(gefitinib).
|
|
|
|
|
|
|
|
|
|
|